Literature DB >> 21321142

In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides.

Agatha N Jassem1, James E A Zlosnik, Deborah A Henry, Robert E W Hancock, Robert K Ernst, David P Speert.   

Abstract

Burkholderia cepacia complex (BCC) bacteria are opportunistic pathogens that can cause severe disease in cystic fibrosis (CF) patients and other immunocompromised individuals and are typically multidrug resistant. Here we observed that unlike other BCC species, most environmental and clinical Burkholderia vietnamiensis isolates were intrinsically susceptible to aminoglycosides but not to cationic antimicrobial peptides or polymyxin B. Furthermore, strains acquired aminoglycoside resistance during chronic CF infection, a phenomenon that could be induced under tobramycin or azithromycin pressure in vitro. In comparing susceptible and resistant B. vietnamiensis isolates, no gross differences in lipopolysaccharide structure were observed, all had lipid A-associated 4-amino-4-deoxy-L-arabinose residues, and all were resistant to the permeabilizing effects of aminoglycosides, a measure of drug entry via self-promoted uptake. However, susceptible isolates accumulated 5 to 6 times more gentamicin than a resistant isolate, and aminoglycoside susceptibility increased in the presence of an efflux pump inhibitor. B. vietnamiensis is therefore unusual among BCC bacteria in its susceptibility to aminoglycosides and capacity to acquire resistance. Aminoglycoside resistance appears to be due to decreased cellular accumulation as a result of active efflux.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321142      PMCID: PMC3088185          DOI: 10.1128/AAC.01434-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

Review 1.  Efflux-mediated antimicrobial resistance.

Authors:  Keith Poole
Journal:  J Antimicrob Chemother       Date:  2005-05-24       Impact factor: 5.790

2.  Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane.

Authors:  M Wu; R E Hancock
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

3.  Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.

Authors:  J Turner; Y Cho; N N Dinh; A J Waring; R I Lehrer
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Antimicrobial peptide therapeutics for cystic fibrosis.

Authors:  Lijuan Zhang; Jody Parente; Scott M Harris; Donald E Woods; Robert E W Hancock; Timothy J Falla
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Contributions of two UDP-glucose dehydrogenases to viability and polymyxin B resistance of Burkholderia cenocepacia.

Authors:  Slade A Loutet; S Josefin Bartholdson; John R W Govan; Dominic J Campopiano; Miguel A Valvano
Journal:  Microbiology       Date:  2009-04-21       Impact factor: 2.777

6.  First structural characterization of Burkholderia vietnamiensis lipooligosaccharide from cystic fibrosis-associated lung transplantation strains.

Authors:  Teresa Ieranò; Alba Silipo; Luisa Sturiale; Domenico Garozzo; Clare Bryant; Rosa Lanzetta; Michelangelo Parrilli; Christine Aldridge; F Kate Gould; Paul A Corris; C M Anjam Khan; Anthony De Soyza; Antonio Molinaro
Journal:  Glycobiology       Date:  2009-07-29       Impact factor: 4.313

7.  A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo.

Authors:  Slade A Loutet; Ronald S Flannagan; Cora Kooi; Pamela A Sokol; Miguel A Valvano
Journal:  J Bacteriol       Date:  2006-03       Impact factor: 3.490

8.  Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense.

Authors:  D P Speert; M Bond; R C Woodman; J T Curnutte
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

9.  Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.

Authors:  David P Speert; Deborah Henry; Peter Vandamme; Mary Corey; Eshwar Mahenthiralingam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

10.  Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance.

Authors:  Silvia Buroni; Maria R Pasca; Ronald S Flannagan; Silvia Bazzini; Anna Milano; Iris Bertani; Vittorio Venturi; Miguel A Valvano; Giovanna Riccardi
Journal:  BMC Microbiol       Date:  2009-09-17       Impact factor: 3.605

View more
  15 in total

1.  Dissecting novel virulent determinants in the Burkholderia cepacia complex.

Authors:  George P Tegos; Mark K Haynes; Herbert P Schweizer
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

2.  Fosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on Burkholderia multivorans clinical isolates.

Authors:  Rebecca J Malott; Chia-Hung Wu; Tracy D Lee; Trevor J Hird; Nathan F Dalleska; James E A Zlosnik; Dianne K Newman; David P Speert
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Anina Ratjen; Yvonne Yau; Jillian Wettlaufer; Larissa Matukas; James E A Zlosnik; David P Speert; John J LiPuma; Elizabeth Tullis; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

4.  In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.

Authors:  A Van Dalem; M Herpol; F Echahidi; C Peeters; I Wybo; E De Wachter; P Vandamme; D Piérard
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 5.  Antibiotic resistance in Burkholderia species.

Authors:  Katherine A Rhodes; Herbert P Schweizer
Journal:  Drug Resist Updat       Date:  2016-07-30       Impact factor: 18.500

6.  Identification, molecular characterisation and antimicrobial susceptibility of genomovars of the Burkholderia cepacia complex in Spain.

Authors:  M J Medina-Pascual; S Valdezate; P Villalón; N Garrido; V Rubio; J A Saéz-Nieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-02       Impact factor: 3.267

7.  MexXY multidrug efflux system of Pseudomonas aeruginosa.

Authors:  Yuji Morita; Junko Tomida; Yoshiaki Kawamura
Journal:  Front Microbiol       Date:  2012-11-28       Impact factor: 5.640

8.  Extreme antimicrobial Peptide and polymyxin B resistance in the genus burkholderia.

Authors:  Slade A Loutet; Miguel A Valvano
Journal:  Front Microbiol       Date:  2011-07-22       Impact factor: 5.640

9.  Investigation of aminoglycoside resistance inducing conditions and a putative AmrAB-OprM efflux system in Burkholderia vietnamiensis.

Authors:  Agatha N Jassem; Connor M Forbes; David P Speert
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-01-06       Impact factor: 3.944

Review 10.  Extreme antimicrobial peptide and polymyxin B resistance in the genus Burkholderia.

Authors:  Slade A Loutet; Miguel A Valvano
Journal:  Front Cell Infect Microbiol       Date:  2011-07-22       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.